Adlyxin slows gut movement which reduces the rate of absorption of food and orally administered medications. Oral medications that need quick absorption and onset of action should be administered 1 hour prior to Adlyxin. Oral contraceptives should be taken at least 1 hour before Adlyxin administration or 11 hours after the dose of Adlyxin.
There is an increased risk for hypoglycemia when Adlyxin is added to a sulfonylurea or insulin. A reduction in the dose of the sulfonylurea or insulin should be considered.
Anaphylaxis and other serious hypersensitivity reactions, including angioedema, may occur. It should not be used by patients with known hypersensitivity to lixisenatide.
Acute pancreatitis is associated with GLP-1 receptor agonists, including Adlyxin. In the clinical trials of Adlyxin, there were 21 cases of pancreatitis among Adlyxin -treated patients and 14 cases in patients who did not receive Adlyxin.
Never share Adlyxin pen between patients, even if the needle is changed. Sharing pens may pose a risk for transmission of blood-borne pathogens.
When Adlyxin is added to a sulfonylurea or insulin, there is an increased risk of hypoglycemia. A reduction in the dose of sulfonylurea or insulin should considered when patients are also taking Adlyxin. In patients receiving sulfonylurea with or without metformin, 14.5% patients on Adlyxin reported symptomatic hypoglycemia compared to 10.6% for those on placebo. In patients receiving insulin with or without metformin, 28.3% patients on Adlyxin reported symptomatic hypoglycemia compared to 23.0% for those on placebo. In patients receiving basal insulin with sulfonylurea, 47.2% patients on Adlyxin reported symptomatic hypoglycemia compared to 21.6% for those on placebo.
Acute kidney injury and worsening of chronic kidney failure have been reported in patients treated with GLP-1 receptor agonists. Kidney function should be monitored during treatment and Adlyxin is not recommended in patients with end stage renal disease.
Patients may develop antibodies to lixisenatide. An analysis of lixisenatide-treated patients showed that 70% were antibody positive at Week 24. Antibody positive patients have a higher incidence of allergic reactions and injection site reactions. If there is worsening of blood glucose control, significant injection site reactions, or allergic reactions, an alternative medication should be considered.
Pregnancy: Lixisenatide has not been adequately studied in pregnant women. Insulin is the preferred choice for treating pregnant diabetic women.
Nursing: There is no information about the secretion of Adlyxin in human milk, the effects on the breastfed infant, or the effects on milk production.
Pricing is currently unavailable because Adlyxin is not yet available in pharmacies.
Inquire about cost assistance via Sanofi Patient Connection.